SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year’s HPAPI […]
Pfizer is set to invest an additional $500m (£411m) to build an advanced gene therapy manufacturing facility in Sanford, North Carolina, US. The new facility is believed to support the company’s continuing investment in gene […]
Cantargia and BioWa have signed an extension of the licence agreement around the BioWa proprietary POTELLIGENT technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology. Since […]
ViiV Healthcare said that the injectable two-drug regimen of cabotegravir and rilpivirine succeeded in the ATLAS-2M phase 3 trial in adult patients with HIV-1 by meeting the primary endpoint. Cabotegravir is an investigational integrase inhibitor […]
SMi Reports: SMipresents workshops for the upcoming Biobanking conference this September with industry expertsLaurent Dolle, Managing Director, BWB and Mary-beth Joshi, Director, Biobank SMi’s 9th Annual Biobanking conference, will commence on 25th-26th September in London. […]